Schroder Investment Management Group
AIMT

Schroder Investment Management Group’s Aimmune Therapeutics AIMT Stock Holding History

Schroder Investment Management Group’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-37,701
Closed -$843K – 1267
2019
Q1 		$843K Buy
37,701
+13,712
+57% +$323K ﹤0.01% 935
2018
Q4 		$574 Sell
23,989
-20,147
-46% -$521K ﹤0.01% 979
2018
Q3 		$1.2M Hold
44,136
– – ﹤0.01% 897
2018
Q2 		$1.21M Buy
44,136
+14,760
+50% +$452K ﹤0.01% 896
2018
Q1 		$935K Buy
29,376
+12,865
+78% +$453K ﹤0.01% 962
2017
Q4 		$624K Sell
16,511
-22,556
-58% -$728K ﹤0.01% 1065
2017
Q3 		$961K Buy
+39,067
New +$842K ﹤0.01% 987

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Schroder Investment Management Group's AIMT Position: Q2 2019 in Review

Schroder Investment Management Group sold out of Aimmune Therapeutics (AIMT) in Q2 2019, closing a stake of 37,701 shares — an estimated $843K sold.

Schroder Investment Management Group first reported a position in AIMT in Q3 2017 and held it in 7 quarters. The position peaked at $1.21M in Q2 2018. 125 funds tracked by Wall St. Rank hold AIMT as of Q2 2019.

  • Schroder Investment Management Group reported no remaining Aimmune Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Schroder Investment Management Group sold 37,701 Aimmune Therapeutics shares in Q2 2019, an estimated $843K.
  • Schroder Investment Management Group first reported a position in Aimmune Therapeutics in Q3 2017 and held it in 7 quarters.
  • Schroder Investment Management Group's Aimmune Therapeutics position peaked at $1.21M in Q2 2018.
  • 125 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2019.

Based on Schroder Investment Management Group's 13F filing for Q2 2019, filed 8 Aug 2019.